The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer.

ABSTRACT: Inhibition of FASN has emerged as a promising therapeutic target in cancer, and numerous inhibitors have been investigated. However, severe pharmacological limitations have challenged their clinical testing. The synthetic FASN inhibitor triclosan, which was initially developed as a topical antibacterial agent, is merely affected by these pharmacological limitations. Yet, little is known about its mechanism in inhibiting the growth of cancer cells. Here we compared the cellular and molecular effects of triclosan in a panel of eight malignant and non-malignant prostate cell lines to the well-known FASN inhibitors C75 and orlistat, which target different partial catalytic activities of FASN. Triclosan displayed a superior cytotoxic profile with a several-fold lower IC50 than C75 or orlistat.

SUBMITTER: Sadowski MC 

PROVIDER: S-EPMC4253440 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature